Conference Highlights ASH

Conference Highlights ASH

Transplant for Mantle-Cell Lymphoma: Is it the Right Thing to Do?

Conference Highlights ASH

Combination Biologic Therapy Without Chemotherapy as Initial Treatment for Mantle-Cell Lymphoma: Multicenter Phase 2 Study of Lenalidomide Plus Rituximab

Conference Highlights ASH

Phase 2 Trial of GS-9973, a Selective Syk Inhibitor, in Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma

Conference Highlights ASH

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib and Rituximab for Previously Treated Patients with Chronic Lymphocytic Leukemia

Conference Highlights ASH

Ibrutinib in Combination with Bendamustine and Rituximab Is Active and Tolerable in Patients with Relapsed or Refractory CLL/SLL: Final Results of a Phase 1b Study

Conference Highlights ASH

Ibrutinib in Combination with Rituximab is Well Tolerated and Induces a High Rate of Durable Remissions in Patients with High-Risk Chronic Lymphocytic Leukemia: New, Updated Results of a Phase 2 Trial in 40 Patients

Conference Highlights ASH

Single-Agent Ibrutinib (PCI-32765) Achieves Equally Good and Durable Responses in Patients with Chronic Lymphocytic Leukemia with and without Deletion 17p

Conference Highlights ASH

A Multicenter, Phase 4 Observational Study of Ofatumumab in Chronic Lymphocytic Leukemia: A European Research Initiative on CLL (ERIC) Study

Conference Highlights ASH

The Bruton’s Tyrosine Inhibitor Ibrutinib (PCI-32765) Monotherapy Demonstrates Long-Term Safety and Durability of Response in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in an Open-Label Extension Study

Conference Highlights ASH

Ofatumumab + Chlorambucil versus Chlorambucil Alone in Patients with Untreated Chronic Lymphocytic Leukemia: Results of the Phase 3 Study Complement 1 (OMB110911)

1
2
3
4

Page 2 of 4
Results 11 - 20 of 35

SUBSCRIBE

© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

AHDB Special Print Editions

AHDB Weekly e‑Newsletter

I have reviewed and consent to the terms of AHDB's Privacy Policy, and AHDB has my permission to retain my information in its database, and to forward pertinent communications to me.